In This Article:
The market has climbed 1.0% in the last 7 days and is up 28% over the past 12 months, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high-growth tech stocks can be crucial for investors looking to capitalize on robust market performance and strong future earnings potential.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Super Micro Computer | 20.81% | 27.98% | ★★★★★★ |
Sarepta Therapeutics | 23.58% | 44.12% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.44% | 65.92% | ★★★★★★ |
G1 Therapeutics | 36.07% | 67.23% | ★★★★★★ |
Amicus Therapeutics | 20.32% | 62.37% | ★★★★★★ |
Travere Therapeutics | 26.68% | 68.80% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Alnylam Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference with a market cap of approximately $35.24 billion.
Operations: Alnylam Pharmaceuticals generates revenue primarily through the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.34 billion. The company focuses on leveraging its proprietary technology to create innovative treatments.
Alnylam Pharmaceuticals is navigating a transformative phase with promising clinical outcomes and strategic R&D investments, positioning it uniquely in the biotech sector. Recent data from the HELIOS-B Phase 3 study underscored vutrisiran's potential in reducing mortality and cardiovascular events by significant margins, marking a pivotal advancement in ATTR amyloidosis treatment. Despite being unprofitable, Alnylam's aggressive R&D spending aligns with its innovation trajectory, evidenced by a substantial 19.3% expected annual revenue growth outpacing the US market forecast of 8.7%. Moreover, earnings are projected to surge by an impressive 65.21% annually over the next three years, highlighting its forward-looking approach amidst industry challenges like high volatility and shareholder dilution over the past year.
-
Dive into the specifics of Alnylam Pharmaceuticals here with our thorough health report.
-
Learn about Alnylam Pharmaceuticals' historical performance.
Live Nation Entertainment
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Live Nation Entertainment, Inc. operates as a live entertainment company worldwide with a market cap of $23.70 billion (NYSE: LYV).